Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common
-
Shares outstanding
-
229M
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
63.2M
-
Shares change
-
-1.23M
-
Total reported value, excl. options
-
$56.2M
-
Value change
-
-$1.2M
-
Number of buys
-
33
-
Number of sells
-
-24
-
Price
-
$0.89
Significant Holders of Lineage Cell Therapeutics, Inc. - Common (LCTX) as of Q4 2019
92 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common as of Q4 2019.
Lineage Cell Therapeutics, Inc. - Common (LCTX) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.2M shares
of 229M outstanding shares and own 27.59% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (34M shares), BlackRock Inc. (7.29M shares), VANGUARD GROUP INC (5.47M shares), Defender Capital, LLC. (3.98M shares), Prescott General Partners LLC (1.85M shares), STATE STREET CORP (1.8M shares), GEODE CAPITAL MANAGEMENT, LLC (1.57M shares), NORTHERN TRUST CORP (1.16M shares), BRIDGEWAY CAPITAL MANAGEMENT INC (529K shares), and Northeast Financial Consultants Inc (524K shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.